Pivotal trial of semaglutide 2.4 mg weekly for chronic weight management in adults without diabetes.
14.9% body-weight reduction at 68 weeks vs 2.4% placebo.
Summary is editorial; consult the original publication for the full methodology and statistical detail.
Five minutes. Free. No pressure.